SZSE:002412 (China)
Â
Class A
Â¥
5.79
(-0.52%)
Jan 15
Business Description
Hunan Hansen Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000PK2
Share Class Description:
SZSE:002412: Class ACompare
Compare
Traded in other countries / regions
002412.China IPO Date
2011-04-22Description
Hunan Hansen Pharmaceutical Co Ltd is producing Chinese and Western medicines. Its main dosage forms include large-volume injections, small-volume injections, oral liquids, tablets, hard capsules, granules, syrups, ointments, tinctures, and pills. The company's main products are Si Mo Tang Oral Liquid, Shuanquan Capsule, Ginkgo Biloba Capsule and Tianma Xingnao Capsule.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.65 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.31 | |||||
| Interest Coverage | 90.08 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 6.63 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.8 | |||||
| 3-Year EBITDA Growth Rate | 17 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| 3-Year FCF Growth Rate | 60.5 | |||||
| 3-Year Book Growth Rate | 7.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.7 | |||||
| 9-Day RSI | 42.02 | |||||
| 14-Day RSI | 41.53 | |||||
| 6-1 Month Momentum % | 21.47 | |||||
| 12-1 Month Momentum % | -0.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | |||||
| Quick Ratio | 2.52 | |||||
| Cash Ratio | 1.14 | |||||
| Days Inventory | 344.53 | |||||
| Days Sales Outstanding | 107.67 | |||||
| Days Payable | 46.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 58.7 | |||||
| Shareholder Yield % | 0.88 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.08 | |||||
| Operating Margin % | 25.94 | |||||
| Net Margin % | 23.41 | |||||
| FCF Margin % | 18.67 | |||||
| ROE % | 11.26 | |||||
| ROA % | 9.5 | |||||
| ROIC % | 11.9 | |||||
| 3-Year ROIIC % | 49.5 | |||||
| ROC (Joel Greenblatt) % | 33.4 | |||||
| ROCE % | 12.89 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.9 | |||||
| PE Ratio without NRI | 12.73 | |||||
| Shiller PE Ratio | 20.68 | |||||
| Price-to-Owner-Earnings | 19.62 | |||||
| PEG Ratio | 3.26 | |||||
| PS Ratio | 3.04 | |||||
| PB Ratio | 1.39 | |||||
| Price-to-Tangible-Book | 1.42 | |||||
| Price-to-Free-Cash-Flow | 16.19 | |||||
| Price-to-Operating-Cash-Flow | 15.33 | |||||
| EV-to-EBIT | 10.1 | |||||
| EV-to-EBITDA | 10.1 | |||||
| EV-to-Revenue | 2.73 | |||||
| EV-to-FCF | 14.21 | |||||
| Price-to-Projected-FCF | 1.1 | |||||
| Price-to-DCF (Earnings Based) | 1.1 | |||||
| Price-to-DCF (FCF Based) | 0.52 | |||||
| Price-to-Median-PS-Value | 0.61 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.73 | |||||
| Price-to-Graham-Number | 0.89 | |||||
| Price-to-Net-Current-Asset-Value | 4.23 | |||||
| Price-to-Net-Cash | 144.75 | |||||
| Earnings Yield (Greenblatt) % | 9.9 | |||||
| FCF Yield % | 6.17 | |||||
| Forward Rate of Return (Yacktman) % | 10.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hunan Hansen Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 965.371 | ||
| EPS (TTM) (Â¥) | 0.449 | ||
| Beta | 0.71 | ||
| Volatility % | 33.47 | ||
| 14-Day RSI | 41.53 | ||
| 14-Day ATR (Â¥) | 0.198076 | ||
| 20-Day SMA (Â¥) | 5.9955 | ||
| 12-1 Month Momentum % | -0.75 | ||
| 52-Week Range (Â¥) | 4.08 - 6.83 | ||
| Shares Outstanding (Mil) | 503.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hunan Hansen Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hunan Hansen Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hunan Hansen Pharmaceutical Co Ltd Frequently Asked Questions
What is Hunan Hansen Pharmaceutical Co Ltd(SZSE:002412)'s stock price today?
The current price of SZSE:002412 is ¥5.79. The 52 week high of SZSE:002412 is ¥6.83 and 52 week low is ¥4.08.
When is next earnings date of Hunan Hansen Pharmaceutical Co Ltd(SZSE:002412)?
The next earnings date of Hunan Hansen Pharmaceutical Co Ltd(SZSE:002412) is .
Does Hunan Hansen Pharmaceutical Co Ltd(SZSE:002412) pay dividends? If so, how much?
Hunan Hansen Pharmaceutical Co Ltd(SZSE:002412) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers